HC Wainwright Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $55.00

UroGen Pharma (NASDAQ:URGN - Get Free Report) had its target price cut by research analysts at HC Wainwright from $64.00 to $55.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 454.44% from the stock's previous close.

Several other equities analysts have also recently commented on the stock. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target on the stock. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $38.20.

UroGen Pharma Trading Up 1.0 %

Shares of NASDAQ URGN opened at $9.92 on Tuesday. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a one year low of $9.03 and a one year high of $20.70. The business has a 50-day moving average price of $10.44 and a two-hundred day moving average price of $11.72. The firm has a market capitalization of $232.66 million, a PE ratio of -3.15 and a beta of 1.12.

Remove Ads

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, analysts predict that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Transactions at UroGen Pharma

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company's stock, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. RTW Investments LP boosted its holdings in UroGen Pharma by 1.3% during the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock valued at $40,841,000 after acquiring an additional 47,447 shares during the period. Toronto Dominion Bank acquired a new position in shares of UroGen Pharma during the 4th quarter worth about $18,628,000. Vestal Point Capital LP boosted its stake in UroGen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock valued at $17,360,000 after purchasing an additional 1,230,000 shares during the period. Acorn Capital Advisors LLC acquired a new stake in UroGen Pharma in the 4th quarter valued at approximately $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in UroGen Pharma by 2.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company's stock valued at $14,667,000 after buying an additional 36,084 shares during the last quarter. Institutional investors own 91.29% of the company's stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.